Drugs / PJS-539
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05008393 | Sep 2021 → Feb 2022 | COVID-19, pneumonia | Hospital do Coracao | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PJS-539 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008393 ↗ |
| Action | Inhibit | “PJS-539 has been demonstrated to inhibit viral uptake and replication of SARS-CoV-2.” NCT05008393 ↗ |
| Route | Oral | “Patients will receive PJS-539 dose 1 orally once daily for 10 days.” NCT05008393 ↗ |